Spero Therapeutics, Inc.

NasdaqGS:SPRO Stock Report

Market Cap: US$47.8m

Spero Therapeutics Future Growth

Future criteria checks 3/6

Spero Therapeutics's revenue is forecast to decline at 0.4% per annum while its annual earnings are expected to grow at 40.6% per year. EPS is expected to grow by 36.5% per annum.

Key information

40.6%

Earnings growth rate

36.5%

EPS growth rate

Biotechs earnings growth29.7%
Revenue growth rate-0.4%
Future return on equityn/a
Analyst coverage

Low

Last updated30 Jan 2025

Recent future growth updates

Recent updates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Feb 04
Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 19

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Nov 02
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Earnings and Revenue Growth Forecasts

NasdaqGS:SPRO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202733-12N/AN/A1
12/31/20261-30N/AN/A1
12/31/202530-47N/AN/A2
12/31/202439-65N/AN/A2
9/30/20241064-18-18N/A
6/30/202411817-14-14N/A
3/31/202411123-14-14N/A
12/31/202310423-33-33N/A
9/30/202378-22929N/A
6/30/202354-101212N/A
3/31/202354-2788N/A
12/31/202254-46-8-8N/A
9/30/20229-102-80-80N/A
6/30/202210-113-84-84N/A
3/31/202213-103-77-77N/A
12/31/202118-90-64-64N/A
9/30/202117-79-53-53N/A
6/30/202118-76-70-70N/A
3/31/202115-74-78-78N/A
12/31/20209-79-86-86N/A
9/30/202011-85-87-87N/A
6/30/202012-84-75-75N/A
3/31/202012-80-63-62N/A
12/31/201918-61-50-50N/A
9/30/201916-47-49-46N/A
6/30/201912-39-45-42N/A
3/31/201911-36-41-39N/A
12/31/20184-42-42-40N/A
9/30/20183-46-39-39N/A
6/30/20183-47N/A-44N/A
3/31/20183-50N/A-44N/A
12/31/20172-46N/A-39N/A
9/30/20171-40N/A-36N/A
6/30/20171-35N/A-32N/A
3/31/20170-30N/A-29N/A
12/31/20160-30N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPRO's forecast earnings growth (40.6% per year) is above the savings rate (2.6%).

Earnings vs Market: SPRO's earnings (40.6% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: SPRO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SPRO's revenue is expected to decline over the next 3 years (-0.4% per year).

High Growth Revenue: SPRO's revenue is forecast to decline over the next 3 years (-0.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 23:27
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spero Therapeutics, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI